acamprosate + naltrexone + disulfiram

This is a combination therapy consisting of three distinct medications—acamprosate, naltrexone, and disulfiram—used in the management of alcohol use disorder (AUD). Each drug has a different mechanism of action targeting various neurochemical pathways involved in alcohol dependence: - **Acamprosate** is a structural analogue of gamma-aminobutyric acid (GABA) and modulates glutamatergic neurotransmission. It helps restore the balance between excitatory and inhibitory neurotransmitters disrupted by chronic alcohol use, thereby reducing cravings and supporting abstinence[1][2][7]. - **Naltrexone** is an opioid receptor antagonist that blocks mu-opioid receptors. By doing so, it diminishes the rewarding effects of alcohol consumption and reduces cravings[1][3][4]. - **Disulfiram** inhibits aldehyde dehydrogenase, leading to accumulation of acetaldehyde when alcohol is consumed. This causes unpleasant physiological reactions (e.g., flushing, nausea), serving as a deterrent to drinking[3][4][7]. While each medication can be used individually for AUD treatment—and combinations such as acamprosate plus naltrexone have been studied with some evidence suggesting enhanced efficacy over monotherapy—the triple combination with disulfiram is not standard or widely studied as a fixed regimen. All three are FDA-approved for AUD but typically prescribed separately based on patient needs[1][3][4].